According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine was about five times higher than those who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) shot.
The researchers reported the findings in JAMA Network Open. The study included nearly 7 million recipients of the two-dose mRNA vaccine from Pfizer/BioNTech and an equal number of similar people who received the one-shot vector-based JNJ vaccine.
The data exhibited the effectiveness of the vaccines at preventing hospitalization at 92% for Pfizer/BioNTech's shots versus 59% for the J&J vaccine.
Related: Final Analysis Show Johnson & Johnson's COVID-19 Offers Only 52.9% Protection.
"These results strengthen the evidence" in favor of giving an mRNA booster shot to people who initially received the J&J vaccine, the authors conclude.
Also See: Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations.
Price Action: JNJ shares traded 0.89% higher at $167.52, PFE shares are up 1.47% at $48.40, BNTX stock is down 2.42% at $143.39 during the market session on the last check Thursday.
Photo by Johaehn from Pixabay
